Samsung launches third rival to AbbVie's Humira drug in EU
LONDON: South Korea's Samsung Bioepis and its partner Biogen have launched a third rival to AbbVie's blockbuster medicine Humira in Europe, ramping up competition for a slice of the world's top-selling prescription drug's sales.
Wednesday's launch follows similar moves a day earlier by Amgen and Novartis's Sandoz unit. A fourth so-called biosimilar copy of Humira is expected soon from Mylan .
The primary European patent on Humira expired on Oct. 16, opening the door to cheaper near-identical copies for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis.
Humira's worldwide sales were $18 billion last year, of which around $4 billion came from Europe, and health care providers are hoping for significant savings with the arrival of cut-price rivals.
Samsung Bioepis is a joint venture between Samsung Biologics and Biogen.
News of the launch comes amid a slide in Samsung BioLogics shares after a local media report that said the company faces disciplinary action due to alleged accounting violations.
Read Also: EU approves fifth copy of AbbVie’s $18 Billion drug Humira
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd